Levrett plc “Possible Acquisition of Nuformix Limited and Suspension of Trading”

The Directors of Levrett has told DirectorsTalk that the Company has signed a non-binding letter of intent to acquire the entire issued share capital of Nuformix Limited, a UK incorporated company operating in the cocrystal technology sector, for new shares in the Company.

 

The Acquisition is subject, inter alia, to the completion of due diligence, documentation and compliance with all regulatory requirements, including the Listing and Prospectus Rules and, as required, the Takeover Code.

 

The Company intends to convene a General Meeting as soon as practicable in order to seek the shareholder approvals necessary to pursue this opportunity.  It should also be noted that if the Acquisition proceeds, further shareholder consent may also be required including to deal with any applicable requirements of the Takeover Code.

 

Suspension and Application for Listing

 

The Acquisition, if it proceeds, will constitute a Reverse Takeover under the Listing Rules since, inter alia, in substance it will result in a fundamental change in the business of the issuer.

 

As the Acquisition will constitute a Reverse Takeover under the Listing Rules, trading in the Company’s ordinary shares have been suspended (pursuant to Listing Rule 5.3.1) with immediate effect pending the publication of a prospectus and the application for the enlarged Company to have its ordinary shares admitted to the Official List and to trading on the main market for listed securities of the London Stock Exchange.

 

The Company is working on the preparation of a prospectus in relation to the Acquisition and will, in due course, be making application for the enlarged Company to have its ordinary shares admitted to the Official List and to trading on the main market for listed securities of the London Stock Exchange.

 

The Company will update shareholders as the matter progresses.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Levrett Plc

    More articles like this

    Levrett Plc

    Levrett Plc Final Results and Annual Report

    Levrett PLC (LON:LVRT), a Company formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, today announced its final results for the period ended 31 March 2017 and

    Levrett Plc

    Levrett Plc Biotech: Bull market or Bubble?

    Levrett Plc (LON:LVRT), a Company formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, today made the following comment regarding the Timmerman Report which was published earlier

    Levrett Plc

    Levrett Plc Big data in biotech

    Alphabet Inc (NASDAC:GOOGL) executive chairman Eric Schmidt on Monday pointed out six game changing technologies, or what he calls moonshots, that he thinks will improve important parts of society. This was highlighted on the fortune.com website.

    Levrett Plc

    Levrett Plc comments on an unprecedented cancer research effort

    Levrett Plc (LON:LVRT) CEO Pascal Hughes, said: “Sean Parker of Napster and Facebook fame joins a list of tech based philanthropists starting initiatives in the Biotech and Lifescience sector with this collaborative initiative in immuno-oncology which

    Levrett Plc

    Levrett Plc Strategy, Biotechnology, Success and Focus

    Levrett Plc (LON:LVRT) Chief Executive Officer Pascal Hughes caught up with DirectorsTalk to chat about strategy, the biotech sector, the future for this sector and due diligence. Levrett Plc, a Company formed to acquire a target